Dec. 10, 2018
A novel therapy for treating dysbiosis, specifically small intestinal bacterial overgrowth (SIBO), by utilizing virus-like particles (VLPs).
This technique is capable of targeting and resolving the entire bacterial community imbalance; as opposed to, only a specific pathogen. In addition, the VLPs can be collected from an array of environmental samples that similarly represent the targeted impaired microbiota. After enrichment, the treatment can be administered through a variety of formulations, from encapsulated vehicles to incorporation into implanted devices (pacemakers, stents, catheters, etc.).
Dysbiosis is characterized by a microbial imbalance in the gastrointestinal tract, usually referred to as an impaired microbiota. Dietary changes, chemical consumption, high stress, and new medications can all trigger a disruption of an individual’s gut microbiome. This imbalance can lead to the implantation of outside vectors such as pathogens within the gut environment. Thus, dysbiosis can be associated with a wide range of disorders including: irritable bowel syndrome (IBS), fibromyalgia, cirrhosis, colitis, and cancer. Of particular interest, is small intestinal bacterial overgrowth (SIBO); a form of dysbiosis related to Crohn’s disease and IBS. Current available treatments are antibiotic administration, probiotic supplements and fecal microbiota transplantation (FMT). However, the alarming growth rate of antibiotic resistance requires an alternative therapy option for bacterial infections. In addition, the probiotic supplements are limited to reintroducing only a select number of live bacterial components into the microbiome. Furthermore, a FMT can result in the transition of contaminants between donor and recipient; therefore, an alternative treatment is crucial.
Researchers at the University of New Mexico have developed a novel therapy for treating dysbiosis, specifically small intestinal bacterial overgrowth (SIBO), by utilizing virus-like particles (VLPs). This technique is capable of targeting and resolving the entire bacterial community imbalance; as opposed to, only a specific pathogen. In addition, the VLPs can be collected from an array of environmental samples that similarly represent the targeted impaired microbiota. After enrichment, the treatment can be administered through a variety of formulations, from encapsulated vehicles to incorporation into implanted devices (pacemakers, stents, catheters, etc.).
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business community (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
utilizing virus-like particles
irritable bowel syndrome
alarming growth rate
technology description researchers
fecal microbiota transplantation
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium